Illumina, Inc.
NASDAQ:ILMNMedical - Diagnostics & Research
+$1.95 today
- Market cap
- $31.75B
- Beta
- 1.49
- P/E (TTM)
- 28.9
- EPS (TTM)
- $5.58
Volume 1.63M
Average 1.65M
ILMN Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Illumina, Inc.NASDAQ: ILMN
Net Margin · Q2 FY2026 · quarter ended Jun 2026
Net margin narrows to 17.9%
Net margin was 17.9% in Q2 FY2026, down 4.4 pp from a year earlier. On a trailing-twelve-month basis it was 18.4%, down 11.0 pp year over year. Over 3 fiscal years it widened by 115.7 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 14 analysts of 18.1% for the fiscal year ending Dec 2026, down from 19.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 17.9%+5.6 pp QoQ
- Last fiscal yearDec 2025
- 19.6%+47.6 pp YoY
- LTMJun 2026
- 18.4%-11.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -4.4 pp | +4.3 pp | +8.6 pp |
| 1 year | +47.6 pp | -1.5 pp | -49.0 pp |
| 3 years | +115.7 pp | +1.0 pp | -114.6 pp |
| 5 years | +3.1 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 19.6%
- Year-over-year change
- +47.6pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 19.6% | +47.6pp |
| FY2024 | 2024-12-29 | -28.0% | -2.2pp |
| FY2023 | 2023-12-31 | -25.8% | +70.3pp |
| FY2022 | 2023-01-01 | -96.1% | -112.9pp |
| FY2021 | 2022-01-02 | 16.8% | — |
Net Margin vs competitors
How ILMN compares with its peers on the latest reported figures
- ILMN's LTM Jun 2026 net margin of 18.4% is the highest of the 11 companies compared; the peer median is -30.7%.
- Its year-over-year change of -11.0 pp is the 8th highest of 11, against a peer median of +3.4 pp.
- Over three fiscal years its change of +115.7 pp compares with a peer median of +41.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 18.4% | -11.0 pp | +115.7 pp | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | 8.4% | +23.1 pp | — |
| LTM Jun 2026 | -6.8% | +8.3 pp | +13.4 pp | |
| LTM Jun 2026 | -7.1% | +5.8 pp | +57.8 pp | |
| LTM Sep 2026 | -10.8% | +1.0 pp | +25.4 pp | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -23.4% | -23.8 pp | +229.0 pp |
| LTM Sep 2026 | -37.9% | +6.3 pp | +103.2 pp | |
| LTM Mar 2026 | -48.2% | -36.0 pp | -27.9 pp | |
| LTM Mar 2026 | -80.3% | +351.4 pp | -96.5 pp | |
| LTM Mar 2026 | -99.7% | -1.2 pp | +81.6 pp | |
| LTM Mar 2026 | -148.1% | -50.0 pp | — | |
| Peer median (excluding ILMN) | -30.7% | +3.4 pp | +41.6 pp | |
Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.53B | 4.58B | 4.5B | 4.37B | 4.34B |
| Cost of Revenue | 1.37B | 1.61B | 1.76B | 1.51B | 1.45B |
| Gross Profit | 3.15B | 2.97B | 2.74B | 2.86B | 2.89B |
| Gross Margin | 69.7% | 64.8% | 60.9% | 65.4% | 66.7% |
| Research & Development | 1.19B | 1.32B | 1.35B | 1.17B | 951M |
| Selling, General & Admin | 2.09B | 1.3B | 1.61B | 1.09B | 1.08B |
| Operating Expenses | 3.28B | 7.15B | 3.81B | 3.69B | 2.03B |
| Depreciation & Amortization | 251M | 394M | 432M | 354M | 270M |
| EBITDA | 1.2B | (3.92B) | (608M) | (725M) | 1.46B |
| EBITDA Margin | 26.4% | -85.4% | -13.5% | -16.6% | 33.6% |
| Operating Income | (123M) | (4.18B) | (1.07B) | (833M) | 864M |
| Operating Margin | -2.7% | -91.2% | -23.7% | -19.1% | 19.9% |
| Interest Income | 0 | 11M | 58M | 46M | 40M |
| Interest Expense | 61M | 26M | 77M | 100M | 101M |
| Other Income / Expenses | 1.01B | (157M) | (48M) | (346M) | 222M |
| Income Before Tax | 884M | (4.34B) | (1.12B) | (1.18B) | 1.09B |
| Pre-Tax Margin | 19.5% | -94.6% | -24.8% | -27.0% | 25.0% |
| Income Tax Expense | 122M | 68M | 44M | 44M | 236M |
| Net Income | 762M | (4.4B) | (1.16B) | (1.22B) | 850M |
| Net Margin | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% |
| EPS (Basic) | 5.08 | (28.05) | (7.35) | (7.69) | 5.48 |
| EPS (Diluted) | 5.05 | (28.05) | (7.35) | (7.69) | 5.45 |
| Weighted Avg Shares | 150M | 157M | 158M | 159M | 155M |
| Weighted Avg Shares (Diluted) | 151M | 157M | 158M | 159M | 156M |
Illumina, Inc.
NASDAQ:ILMN
Intrinsic Alpha fair value
Locked
Current Price
$210.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.